ENHANCEMENT OF THE DISSOLUTION RATE OF NATEGLINIDE TABLETS USING LIQUISOLID COMPACT TECHNIQUE
Â Objective: The main objective of this work is to develop new formulation to enhance the solubility of a highly permeable and a poorly soluble oral drug antihyperglycemic agent, nateglinide by liquisolid compacts.
Methods: The liquisolid compact technique is based on dissolving the insoluble drug in propylene glycol, polyethylene glycol 400, tween-80 as non-volatile solvents in which drug is having high solubility and admixture of drug loaded solution with microcrystalline cellulose as carrier, aerosil as coating material, crospovidone as disintegrant, and magnesium stearate as lubricant to convert into acceptably flowing and compressible powder. The prepared liquisolid compacts were evaluated for their flowing properties such as bulk density, tapped density, angle of repose, Hausner's ratio, and Carr's index. Further tablets were evaluated for hardness, thickness, weight variation, friability, disintegration test, and in vitro release study.
Result: Higher drug release profiles due to increased wetting property and surface area of the drug available for dissolution was obtained in case of liquisolid compacts. Among all formulations, liquisolid system prepared by propylene glycol was considered as best formulation which release drug up to 98% in 60 minutes and in comparison to marketed formulation, optimized formulation showed better dissolution profile.
Conclusion: It can be concluded that liquisolid compact technique could be a promising strategy in improving the dissolution of poor water soluble drugs.
2. Thakur N, Khokra SL, Sharma D, Thakur NS, Purohit R, Arya V. A review on pharmaceutical applications of liquisolid technique. Am J PharmTech Res 2011;1(3):1-18.
3. Baby DA, Saroj S, Sabitha M. Mechanism of solubility of liquisolid formulation in non-volatile solvent: A review. Int J Pharm Pharm Sci 2012;4(3):710-5.
4. Gopi G, Kannan K. Formulation development and optimization of nateglinide-loaded ethyl cellulose nanoparticles by box-behnken design. Int J Pharm Pharm Sci 2015;7(9):310-5.
5. Halas CJ. Nateglinide. Am J Health Syst Pharm 2001;58(13):1200-5.
6. El-Houssieny BM, Wahman L, Arafa NM. Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. Biosci Trends 2010;4(1):17-24.
7. El-Maghraby GM, Osman MA, Abd-Elrahman HE, Elsisi AE. Self-emulsifying liquisolid tablets for enhanced oral bioavailability of repaglinide: In vitro and in vivo evaluation. J Appl Pharm Sci 2014;4(9):12-21.
8. Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2008;69(3):993-1003.
9. Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN, Bhise SD. Dissolution rate enhancement of fenofibrate using liquisolid tablet technique, Part II: Evaluation of in vitro dissolution profile comparison methods. Lat Am J Pharm 2009;28(4):538-43.
10. Singh SK, Srinivasan KK, Gowthamarajan K, Prakash D, Gaikwad NB, Singare DS. Influence of formulation parameters on dissolution rate enhancement of glyburide using liquisolid technique. Drug Dev Ind Pharm 2012;38(8):961-70.
11. Soujanya B, Srujan KM, Subrahmanyam KV, Shubhrajit M. Enhancement of solubility of efaverinz by liquid solid compact technique. Int J Innov Pharm Sci Res 2013;1(3):347-59.
12. Niazi SK. Handbook of Preformulation. USA: Informa Health Care, Inc.; 2007. p. 69, 73, 241, 218, 219, 294, 296, 310-31.
13. Adeyeye MC, Brittain HG. Preformulation in Solid Dosage Form Development. Vol. 178. USA: Informa Health Care, Inc., CRC Press; 2008. p. 369, 559, 562, 565-7.
14. Patel SS, Patel MS, Patel NM. Flowability and packability testing of directly compressible excipients. Indian Pharm 2008;7(71):65-9.
15. Bhise SD, Nand MR. Formulation and evaluation of mouth dissolving tablets of nateglinide. Int J Pharm Pharm Sci 2013;5(4):318-21.
16. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo) 1996;44(1):2121-7.
17. Shoufeng LI, Senshang LI, CheinYie W, Bruce PD, Haresh LM. Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS PharmSci Tech 2001;2(1):11-2.
18. Indian Pharmacopoeia. Indian Pharmacopoeia Commission. 6th ed., Vol. I. Ghaziabad: Indian Pharmacopoeia Commission; 2010. p. 587.
19. Bi YX, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm 1999;25(5):571-81.
20. Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondensetron HCl by polymer carrier system and formulation of rapid disintegrating tablets. AAPS PharmSci Tech 2007;8(2):127-33.
21. Lachman L, Libberman HA, Kanig JL. Theory and Practice of Industrial Pharmacy. 3rd ed. Bombay: Varghese Publishing House; 1990. p. 183, 296-9, 316.
22. Brijesh SD, Avani EA, Madhabai MP. Gastro retentive drug delivery system of ranitidine HCl: Formulation and in vitro evaluation. AAPS PharmSci Tech 2004;5(2):77-82.
23. Sirisha VN, Sruthi B, Eshwaraiah MC. Preparation and in vitro evaluation of liquid solid compacts of glibenclamide. Int Res J Pharm 2012;3(10):111-4.
24. Neelamma G, Chaitanya MV, Satyavathi B. Design and evaluation of solubility enhancement of poorly soluble drug rosuvastatin using liquid solid compacts. Int J Pharmacol Res 2015;5(5):231-8.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.